Pulmonary Fibrosis Drug Market, Global Outlook and Forecast 2023-2029

Report ID: MMG175098 | Category: Pharma & Healthcare | Pages: 78 | Format: PDF | Published Date: August 16,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3250.00 Multi User-$4225.00

Report Description
View Table of Contents

Report Summary

Pulmonary fibrosis is a lung disorder characterized by damage or scarring of the lung tissue. Once the tissue is damaged, it obstructs the passageway for air and thus hinders the normal functioning of the lungs. It is usually caused as a result of certain medical conditions, exposure to toxins, pollutants or radiation or by certain medications.
This report aims to provide a comprehensive presentation of the global market for Pulmonary Fibrosis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Fibrosis Drug. This report contains market size and forecasts of Pulmonary Fibrosis Drug in global, including the following market information:
Global Pulmonary Fibrosis Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Pulmonary Fibrosis Drug Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Pulmonary Fibrosis Drug companies in 2022 (%)
The global Pulmonary Fibrosis Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Pirfenidone Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Pulmonary Fibrosis Drug include Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, MediciNova, Inc., Genentech, Inc., Cipla Inc. and Biogen, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Pulmonary Fibrosis Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pulmonary Fibrosis Drug Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Pulmonary Fibrosis Drug Market Segment Percentages, by Type, 2022 (%)
Pirfenidone
Nintedanib
Global Pulmonary Fibrosis Drug Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Pulmonary Fibrosis Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Global Pulmonary Fibrosis Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Pulmonary Fibrosis Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pulmonary Fibrosis Drug revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Pulmonary Fibrosis Drug revenues share in global market, 2022 (%)
Key companies Pulmonary Fibrosis Drug sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Pulmonary Fibrosis Drug sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Boehringer Ingelheim
Roche
FibroGen, Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
MediciNova, Inc.
Genentech, Inc.
Cipla Inc.
Biogen
Galapagos NV
Outline of Major Chapters:
Chapter 1: Introduces the definition of Pulmonary Fibrosis Drug, market overview.
Chapter 2: Global Pulmonary Fibrosis Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Pulmonary Fibrosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pulmonary Fibrosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Pulmonary Fibrosis Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
    1.1 Pulmonary Fibrosis Drug Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Pulmonary Fibrosis Drug Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Pulmonary Fibrosis Drug Overall Market Size
    2.1 Global Pulmonary Fibrosis Drug Market Size: 2022 VS 2029
    2.2 Global Pulmonary Fibrosis Drug Revenue, Prospects & Forecasts: 2018-2029
    2.3 Global Pulmonary Fibrosis Drug Sales: 2018-2029
3 Company Landscape
    3.1 Top Pulmonary Fibrosis Drug Players in Global Market
    3.2 Top Global Pulmonary Fibrosis Drug Companies Ranked by Revenue
    3.3 Global Pulmonary Fibrosis Drug Revenue by Companies
    3.4 Global Pulmonary Fibrosis Drug Sales by Companies
    3.5 Global Pulmonary Fibrosis Drug Price by Manufacturer (2018-2023)
    3.6 Top 3 and Top 5 Pulmonary Fibrosis Drug Companies in Global Market, by Revenue in 2022
    3.7 Global Manufacturers Pulmonary Fibrosis Drug Product Type
    3.8 Tier 1, Tier 2 and Tier 3 Pulmonary Fibrosis Drug Players in Global Market
        3.8.1 List of Global Tier 1 Pulmonary Fibrosis Drug Companies
        3.8.2 List of Global Tier 2 and Tier 3 Pulmonary Fibrosis Drug Companies
4 Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Pulmonary Fibrosis Drug Market Size Markets, 2022 & 2029
        4.1.2 Pirfenidone
        4.1.3 Nintedanib
    4.2 By Type - Global Pulmonary Fibrosis Drug Revenue & Forecasts
        4.2.1 By Type - Global Pulmonary Fibrosis Drug Revenue, 2018-2023
        4.2.2 By Type - Global Pulmonary Fibrosis Drug Revenue, 2024-2029
        4.2.3 By Type - Global Pulmonary Fibrosis Drug Revenue Market Share, 2018-2029
    4.3 By Type - Global Pulmonary Fibrosis Drug Sales & Forecasts
        4.3.1 By Type - Global Pulmonary Fibrosis Drug Sales, 2018-2023
        4.3.2 By Type - Global Pulmonary Fibrosis Drug Sales, 2024-2029
        4.3.3 By Type - Global Pulmonary Fibrosis Drug Sales Market Share, 2018-2029
    4.4 By Type - Global Pulmonary Fibrosis Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Pulmonary Fibrosis Drug Market Size, 2022 & 2029
        5.1.2 Hospital
        5.1.3 Clinic
    5.2 By Application - Global Pulmonary Fibrosis Drug Revenue & Forecasts
        5.2.1 By Application - Global Pulmonary Fibrosis Drug Revenue, 2018-2023
        5.2.2 By Application - Global Pulmonary Fibrosis Drug Revenue, 2024-2029
        5.2.3 By Application - Global Pulmonary Fibrosis Drug Revenue Market Share, 2018-2029
    5.3 By Application - Global Pulmonary Fibrosis Drug Sales & Forecasts
        5.3.1 By Application - Global Pulmonary Fibrosis Drug Sales, 2018-2023
        5.3.2 By Application - Global Pulmonary Fibrosis Drug Sales, 2024-2029
        5.3.3 By Application - Global Pulmonary Fibrosis Drug Sales Market Share, 2018-2029
    5.4 By Application - Global Pulmonary Fibrosis Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
    6.1 By Region - Global Pulmonary Fibrosis Drug Market Size, 2022 & 2029
    6.2 By Region - Global Pulmonary Fibrosis Drug Revenue & Forecasts
        6.2.1 By Region - Global Pulmonary Fibrosis Drug Revenue, 2018-2023
        6.2.2 By Region - Global Pulmonary Fibrosis Drug Revenue, 2024-2029
        6.2.3 By Region - Global Pulmonary Fibrosis Drug Revenue Market Share, 2018-2029
    6.3 By Region - Global Pulmonary Fibrosis Drug Sales & Forecasts
        6.3.1 By Region - Global Pulmonary Fibrosis Drug Sales, 2018-2023
        6.3.2 By Region - Global Pulmonary Fibrosis Drug Sales, 2024-2029
        6.3.3 By Region - Global Pulmonary Fibrosis Drug Sales Market Share, 2018-2029
    6.4 North America
        6.4.1 By Country - North America Pulmonary Fibrosis Drug Revenue, 2018-2029
        6.4.2 By Country - North America Pulmonary Fibrosis Drug Sales, 2018-2029
        6.4.3 US Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.4.4 Canada Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.4.5 Mexico Pulmonary Fibrosis Drug Market Size, 2018-2029
    6.5 Europe
        6.5.1 By Country - Europe Pulmonary Fibrosis Drug Revenue, 2018-2029
        6.5.2 By Country - Europe Pulmonary Fibrosis Drug Sales, 2018-2029
        6.5.3 Germany Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.5.4 France Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.5.5 U.K. Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.5.6 Italy Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.5.7 Russia Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.5.8 Nordic Countries Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.5.9 Benelux Pulmonary Fibrosis Drug Market Size, 2018-2029
    6.6 Asia
        6.6.1 By Region - Asia Pulmonary Fibrosis Drug Revenue, 2018-2029
        6.6.2 By Region - Asia Pulmonary Fibrosis Drug Sales, 2018-2029
        6.6.3 China Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.6.4 Japan Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.6.5 South Korea Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.6.6 Southeast Asia Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.6.7 India Pulmonary Fibrosis Drug Market Size, 2018-2029
    6.7 South America
        6.7.1 By Country - South America Pulmonary Fibrosis Drug Revenue, 2018-2029
        6.7.2 By Country - South America Pulmonary Fibrosis Drug Sales, 2018-2029
        6.7.3 Brazil Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.7.4 Argentina Pulmonary Fibrosis Drug Market Size, 2018-2029
    6.8 Middle East & Africa
        6.8.1 By Country - Middle East & Africa Pulmonary Fibrosis Drug Revenue, 2018-2029
        6.8.2 By Country - Middle East & Africa Pulmonary Fibrosis Drug Sales, 2018-2029
        6.8.3 Turkey Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.8.4 Israel Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.8.5 Saudi Arabia Pulmonary Fibrosis Drug Market Size, 2018-2029
        6.8.6 UAE Pulmonary Fibrosis Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
    7.1 Boehringer Ingelheim
        7.1.1 Boehringer Ingelheim Company Summary
        7.1.2 Boehringer Ingelheim Business Overview
        7.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Major Product Offerings
        7.1.4 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales and Revenue in Global (2018-2023)
        7.1.5 Boehringer Ingelheim Key News & Latest Developments
    7.2 Roche
        7.2.1 Roche Company Summary
        7.2.2 Roche Business Overview
        7.2.3 Roche Pulmonary Fibrosis Drug Major Product Offerings
        7.2.4 Roche Pulmonary Fibrosis Drug Sales and Revenue in Global (2018-2023)
        7.2.5 Roche Key News & Latest Developments
    7.3 FibroGen, Inc.
        7.3.1 FibroGen, Inc. Company Summary
        7.3.2 FibroGen, Inc. Business Overview
        7.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Major Product Offerings
        7.3.4 FibroGen, Inc. Pulmonary Fibrosis Drug Sales and Revenue in Global (2018-2023)
        7.3.5 FibroGen, Inc. Key News & Latest Developments
    7.4 Merck & Co., Inc.
        7.4.1 Merck & Co., Inc. Company Summary
        7.4.2 Merck & Co., Inc. Business Overview
        7.4.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Major Product Offerings
        7.4.4 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales and Revenue in Global (2018-2023)
        7.4.5 Merck & Co., Inc. Key News & Latest Developments
    7.5 Bristol-Myers Squibb Company
        7.5.1 Bristol-Myers Squibb Company Company Summary
        7.5.2 Bristol-Myers Squibb Company Business Overview
        7.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Major Product Offerings
        7.5.4 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales and Revenue in Global (2018-2023)
        7.5.5 Bristol-Myers Squibb Company Key News & Latest Developments
    7.6 MediciNova, Inc.
        7.6.1 MediciNova, Inc. Company Summary
        7.6.2 MediciNova, Inc. Business Overview
        7.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Major Product Offerings
        7.6.4 MediciNova, Inc. Pulmonary Fibrosis Drug Sales and Revenue in Global (2018-2023)
        7.6.5 MediciNova, Inc. Key News & Latest Developments
    7.7 Genentech, Inc.
        7.7.1 Genentech, Inc. Company Summary
        7.7.2 Genentech, Inc. Business Overview
        7.7.3 Genentech, Inc. Pulmonary Fibrosis Drug Major Product Offerings
        7.7.4 Genentech, Inc. Pulmonary Fibrosis Drug Sales and Revenue in Global (2018-2023)
        7.7.5 Genentech, Inc. Key News & Latest Developments
    7.8 Cipla Inc.
        7.8.1 Cipla Inc. Company Summary
        7.8.2 Cipla Inc. Business Overview
        7.8.3 Cipla Inc. Pulmonary Fibrosis Drug Major Product Offerings
        7.8.4 Cipla Inc. Pulmonary Fibrosis Drug Sales and Revenue in Global (2018-2023)
        7.8.5 Cipla Inc. Key News & Latest Developments
    7.9 Biogen
        7.9.1 Biogen Company Summary
        7.9.2 Biogen Business Overview
        7.9.3 Biogen Pulmonary Fibrosis Drug Major Product Offerings
        7.9.4 Biogen Pulmonary Fibrosis Drug Sales and Revenue in Global (2018-2023)
        7.9.5 Biogen Key News & Latest Developments
    7.10 Galapagos NV
        7.10.1 Galapagos NV Company Summary
        7.10.2 Galapagos NV Business Overview
        7.10.3 Galapagos NV Pulmonary Fibrosis Drug Major Product Offerings
        7.10.4 Galapagos NV Pulmonary Fibrosis Drug Sales and Revenue in Global (2018-2023)
        7.10.5 Galapagos NV Key News & Latest Developments
8 Global Pulmonary Fibrosis Drug Production Capacity, Analysis
    8.1 Global Pulmonary Fibrosis Drug Production Capacity, 2018-2029
    8.2 Pulmonary Fibrosis Drug Production Capacity of Key Manufacturers in Global Market
    8.3 Global Pulmonary Fibrosis Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
    9.1 Market Opportunities & Trends
    9.2 Market Drivers
    9.3 Market Restraints
10 Pulmonary Fibrosis Drug Supply Chain Analysis
    10.1 Pulmonary Fibrosis Drug Industry Value Chain
    10.2 Pulmonary Fibrosis Drug Upstream Market
    10.3 Pulmonary Fibrosis Drug Downstream and Clients
    10.4 Marketing Channels Analysis
        10.4.1 Marketing Channels
        10.4.2 Pulmonary Fibrosis Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
    12.1 Note
    12.2 Examples of Clients
    12.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Pulmonary Fibrosis Drug Market, Global Outlook and Forecast 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?